Dipeptidyl-peptidase IV and B-type natriuretic peptide. from bench to bedside

Clinical Chemistry and Laboratory Medicine

Volumn 47, Issue 3, 2009, Pages 248-252

  Vanderheyden, Marc ^a   Bartunek, Jozef ^a   Goethals, Marc ^a   Verstreken, Sofie ^a   Lambeir, Anne Marie ^b   De Meester, Ingrid ^b   Scharpé, Simon ^b  

^a CARDIOVASCULAR CENTER   (Belgium)

^b UNIVERSITY OF ANTWERP   (Belgium)

Author keywords

B type natriuretic peptide; CD26; Congestive heart failure; Dipeptidyl peptidase IV

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; CYCLIC GMP; DIPEPTIDYL PEPTIDASE IV;

AMINO TERMINAL SEQUENCE; DIURESIS; ENZYME ACTIVITY; FIBROBLAST; HEART FAILURE; HEART MUSCLE CELL; HEART PROTECTION; HUMAN; NATRIURESIS; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; PROTEIN FUNCTION; REVIEW; VASODILATATION;

ANIMALS; ANTIGENS, CD26; BIOLOGICAL MARKERS; HEART FAILURE; HUMANS; IMMUNOASSAY; NATRIURETIC PEPTIDE, BRAIN;

EID: 63849218238     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/CCLM.2009.065     Document Type: Review

References (35)

1. Lainscak M, Cleland JG, Lenzen MJ, Follath F, Komajda M, Swedberg K. International variations in the treatment and co-morbidity of left ventricular systolic dysfunction: data from the EuroHeart Failure Survey. Eur J Heart Fail 2007;9:292-9.
2. Maisel A, Mueller C, Adams K, Anker S, Aspromonte N, Cleland J, et al. State of the art: using natriuretic peptide levels in clinical practice. Eur J Heart Fail 2008;10: 824-39.
3. Pankow K, Wang Y, Gembardt F, Krause E, Sun X, Krause G, et al. Successive action of meprin A and neprilysin catabolizes B-type natriuretic peptide. Circ Res 2007;101:875-82.
4. Lambeir AM, Durinx C, Scharpé S, De Meester I. Dipeptidyl- peptidase IV from bench to bedside: an update on structural properties, functions, and clinical aspects of the enzyme DPP IV. Crit Rev Clin Lab Sci 2003;40: 209-94.
5. Vanderheyden M, Bartunek J, Goethals M. Brain and other natriuretic peptides: molecular aspects. Eur J Heart Fail 2004;6:261-8.
6. Onuoha GN, Nicholls DP, Patterson A, Beringer T. Neuropeptide secretion in exercise. Neuropeptides 1998;32: 319-25.
7. Yasue H, Yoshimura M, Sumida H, Kikuta K, Kugiyama K, Jougasaki M, et al. Localization and mechanism of secretion of B-type natriuretic peptide in comparison with those of A-type natriuretic peptide in normal subjects and patients with heart failure. Circulation 1994; 90:195-203.
8. Ma KK, Banas K, de Bold AJ. Determinants of inducible brain natriuretic peptide promoter activity. Regul Pept 2005;128:169-76.
9. Vanderheyden M, Goethals M, Verstreken S, De Bruyne B, Muller K, Van Schuerbeeck E, et al. Wall stress modulates brain natriuretic peptide production in pressure overload cardiomyopathy. J Am Coll Cardiol 2004;44: 2349-54.
10. Dries DL. Relevance of molecular forms of brain natriuretic peptide for natriuretic peptide research. Hypertension 2007;49:971-3.
11. Liang F, O'Rear J, Schellenberger U, Tai L, Lasecki M, Schreiner GF, et al. Evidence for functional heterogeneity of circulating B-type natriuretic peptide. J Am Coll Cardiol 2007;49:1071-8.
12. Valli N, Gobinet A, Bordenave L. Review of 10 years of the clinical use of brain natriuretic peptide in cardiology. J Lab Clin Med 1999;134:43-4.
13. Kone BC. Molecular biology of natriuretic peptides and nitric oxide synthases. Cardiovasc Res 2001;51:429-41.
14. Das SR, Abdullah SM, Leonard D, Drazner MH, Khera A, McGuire DK, et al. Association between renal function and circulating levels of natriuretic peptides (from the Dallas Heart Study). Am J Cardiol 2008;102:1394-8.
15. Tsutamoto T, Kanamori T, Wada A, Kinoshita M. Uncoupling of atrial natriuretic peptide extraction and cyclic guanosine monophosphate production in the pulmonary circulation in patients with severe heart failure. J Am Coll Cardiol 1992;20:541-6.
16. Tsutamoto T, Wada A, Maeda K, Hisanaga T, Maeda Y, Fukai D, et al. Attenuation of compensation of endogenous cardiac natriuretic peptide system in chronic heart failure: prognostic role of plasma brain natriuretic peptide concentration in patients with chronic symptomatic left ventricular dysfunction. Circulation 1997;96:509-16.
17. De Meester I, Korom S, Van Damme J, Scharpé S. CD26, let it cut or cut it down. Immunol Today 1999;20:367-75.
18. Hino M, Fuyamada H, Hayakawa T, Nagatsu T, Oya H. X-Prolyldipeptidyl- aminopeptidase activity, with X proline p-nitroanilides as substrates, in normal and pathological human sera. Clin Chem 1976;22:1256-61.
19. Drucker DJ. Dipeptidyl peptidase-4 inhibition and the treatment of type 2 diabetes: preclinical biology and mechanisms of action. Diabetes Care 2007;30:1335-43.
20. Pratley RE, Gilbert M. Targeting incretins in type 2 diabetes: role of GLP-1 receptor agonists and DPP-4 inhibitors. Rev Diabet Stud 2008;5:73-94.
21. Goetze JP. Biochemistry of pro-B-type natriuretic peptide-derived peptides: the endocrine heart revisited. Clin Chem 2004;50:1503-10.
22. Shimizu H, Masuta K, Aono K, Asada H, Sasakura K, Tamaki M, et al. Molecular forms of human brain natriuretic peptide in plasma. Clin Chim Acta 2002;316: 129-35.
23. Shimizu H, Masuta K, Asada H, Sugita K, Sairenji T. Characterization of molecular forms of probrain natriuretic peptide in human plasma. Clin Chim Acta 2003; 334:233-9.
24. Brandt I, Lambeir AM, Ketelslegers JM, Vanderheyden M, Scharpé S, De Meester I. Dipeptidyl-peptidase IV converts intact B-type natriuretic peptide into its des-SerPro form. Clin Chem 2006;52:82-7.
25. Niederkofler E, Kiernan U, O'Rear J, Menon S, Saghir S, Protter A, et al. Detection of endogenous B-type natriuretic peptide at very low concentrations in patients with heart failure. Circ Heart Fail 2008;1:258-64.
26. Ban K, Noyan-Ashraf MH, Hoefer J, Bolz SS, Drucker DJ, Husain M. Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways. Circulation 2008;117:2340-50.
27. Papies B, Frille J, Gunther KH, Wagenknecht C. Isoenzyme (lactate dehydrogenase, aspartate aminotransferase) and dipeptidyl peptidase IV activity changes in blood plasma likely indicative of organ involvement due to arterial hypertension. Cor Vasa 1991;33:218-26.
28. Hawkridge AM, Heublein DM, Bergen HR III, Cataliotti A, Burnett JC Jr, Muddiman DC. Quantitative mass spectral evidence for the absence of circulating brain natriuretic peptide (BNP-32) in severe human heart failure. Proc Natl Acad Sci USA 2005;102:17442-7.
29. Seferian KR, Tamm NN, Semenov AG, Tolstaya AA, Koshkina EV, Krasnoselsky MI, et al. Immunodetection of glycosylated NT-proBNP circulating in human blood. Clin Chem 2008;54:866-73.
30. Luckenbill KN, Christenson RH, Jaffe AS, Mair J, Ordonez- Llanos J, Pagani F, et al. Cross-reactivity of BNP, NT-proBNP, and proBNP in commercial BNP and NTproBNP assays: preliminary observations from the IFCC Committee for Standardization of Markers of Cardiac Damage. Clin Chem 2008;54:619-21.
31. Lam CS, Burnett JC Jr, Costello-Boerrigter L, Rodeheffer RJ, Redfield MM. Alternate circulating pro-B-type natriuretic peptide and B-type natriuretic peptide forms in the general population. J Am Coll Cardiol 2007;49:1193-202.
32. Heublein DM, Huntley BK, Boerrigter G, Cataliotti A, Sandberg SM, Redfield MM, et al. Immunoreactivity and guanosine 39,59-cyclic monophosphate activating actions of various molecular forms of human B-type natriuretic peptide. Hypertension 2007;49:1114-9.
33. Boerrigter G, Costello-Boerrigter LC, Harty GJ, Lapp H, Burnett JC Jr. Des-serine-proline brain natriuretic peptide 3-32 in cardiorenal regulation. Am J Physiol Regul Integr Comp Physiol 2007;292:R897-901.
34. Boerrigter G, Costello-Boerrigter LC, Harty GJ, Arstad LK, Ameenuddin S, Burnett JC. Dipeptidyl peptidase IV inhibition with sitagliptin augments cGMP-activating and hypotensive properties of B-type natriuretic peptide. J Card Fail 2008;14:S75.
35. Colucci WS, Elkayam U, Horton DP, Abraham WT, Bourge RC, Johnson AD, et al. Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. Nesiritide Study Group. N Engl Med 2000;343:246-53.